Results 221 to 230 of about 7,176,766 (309)

Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study was to develop a novel workflow to identify human urine biomarkers for drugs of abuse and new psychoactive substances. Metabolites of amphetamine, cocaine, LSD, MDMA, methamphetamine, THC, MDMB‐CHMICA, and MDPPP were first identified in a zebrafish embryo (ZE) metabolism study followed by comparison to most abundant human ...
Simon K. Wellenberg, Tanja M. Gampfer, Lea Wagmann, Philip Schippers, Jennifer Herrmann, Rolf Müller, Folker Westphal, Markus R. Meyer   +7 more
wiley   +1 more source

Network geometry, topology, and spectral analysis in global stock markets: Insights from using the Ricci curvature, Euler characteristic, and random matrix theory. [PDF]

PLoS One
Domínguez-Monterroza A, Jiménez-Martín A, Mateos Caballero A.   +2 more
europepmc   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

The effectiveness of electronic payments on the market value of agricultural companies listed on the Iraq Stock Exchange. [PDF]

F1000Res
Battal AH, Shabeeb A, Faraj BAA, Al-Anezi W, Faisal FG.   +4 more
europepmc   +1 more source

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola, Aleksandar Gigov, Hubertus G. M. Leufkens, Andrew Bate, Marie Louise De Bruin, Helga Gardarsdottir   +5 more
wiley   +1 more source

Towards nature-related risk disclosures in China. [PDF]

Bioscience
Archibald CL, Gao L, Hadjikakou M, Li C, Liu J, Nicholson E, Ou W, Tao Q, Wang Z, Zhang X, Zeng C, Bryan BA.   +11 more
europepmc   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source

Digital Leadership, Information Entropy, and Stock Price Volatility: Evidence from CEO Social Media Behavior. [PDF]

Entropy (Basel)
Zou Y, Tian J, Zhang Y, Shi G, Cai X.
europepmc   +1 more source

Evaluating effectiveness of risk minimization through healthcare professional surveys: A review of post‐authorization studies, 2022–2024

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Risk minimization measures (RMMs) are key regulatory tools to ensure safe medicinal product use. Regulatory guidelines recommend pre‐specifying the targets, or ‘thresholds’, for assessing RMM effectiveness. We aimed to review recent industry‐sponsored post‐authorization safety studies (PASS) that evaluated the effectiveness of RMMs ...
Kexin Zhu, William A. Blumentals, Froilan G. Celzo, G. Caleb Alexander, Lingyun Zhou, Juhaeri Juhaeri, Corinne Jouquelet‐Royer, Jian‐Yu E   +7 more
wiley   +1 more source

Tail risk, large fluctuations and downfalls in renewable energy markets. [PDF]

PLoS One
Hasanov AS, Ibragimov R, Yildirim R, Chong SK, Abrorov S.   +4 more
europepmc   +1 more source